



TOS 2022 40th Annual Scientific Meeting

Continuing Medical Education

Information for Learners

Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this blended learning format activity for a maximum of 95.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity combines a live in-person format with recorded modules.

ACCME Activity ID 201829479

Learning Objectives

1. Apply the latest recommendations for evaluation and treatment; tailor intervention strategies based on patient characteristics such as age or metabolic or behavioral phenotype; understand the differences between weight loss and weight loss maintenance.
2. Understand the evidence-based science regarding neuroendocrine, environmental, endocrine, microbiota and/or cognitive behavioral mechanisms regulating energy balance and body weight. Apply that knowledge to develop and implement treatment options for adults and pediatric patients with overweight, obesity or obesity-related co-morbidities.
3. Implement appropriate strategies for diagnosing adolescent and pediatric obesity, evaluate current treatment options and emerging therapeutics and provide care and treatment to adolescent and pediatric patients accordingly. Teach evidence-based strategies for obesity prevention in the pediatric and adolescent population.
4. Apply lessons learned about the impact of: nutrition and obesity initiatives to reduce health disparities, and federal nutrition and obesity policies on health disparities.
5. Apply new knowledge related to dietary intervention and physical activity from the perspectives of Metabolism and Integrative Physiology, Neuroscience, Intervention and Clinical Studies, Population Health, Clinical/Professional Practice, and Policy/Public Health.

- Incorporate knowledge about coding for reimbursement into the clinical practice of health care providers to support their ability to treat the underlying disease of overweight and obesity. Incorporate knowledge about best practices to develop and run effective clinics that treat overweight and obesity.

Commercial Support

Educational grants in partial support of the conference were received from Pfizer, Inc., Rhythm Pharmaceuticals, Inc., and Lilly.

Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities¹ (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed. TOS requires additional disclosures beyond the ACCME definition of an ineligible company. These include food, weight loss, and supplement industry disclosures. In the list below, the nature of the relationship and company are followed by the industry of that company.

Speaker Disclosures:

| Name of Presenter | Relevant Financial Relationships |
|-----------------------------|-------------------------------------|
| Mahmoud Abulmeaty, MD, FACN | No Relevant Financial Relationships |
| Ted Adams, PhD | No Relevant Financial Relationships |
| Liliana Aguayo, PhD, MPH | No Relevant Financial Relationships |
| Muzayyana Akhmadjonova, MD | No Relevant Financial Relationships |

¹ An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: <https://accme.org/faq/what-accmes-definition-ineligible-company>

| Name of Presenter | Relevant Financial Relationships |
|---------------------------------|---|
| Michael Albert, MD | Consultant relationship with Gelesis (Medical Device) and Novo Nordisk (Pharmaceuticals); Advisor and Stock Options relationship with Elo Health (Supplement) |
| Jaclyn Albin, MD, CCMS, DipABLM | No Relevant Financial Relationships |
| Amber Alhadeff, PhD | No Relevant Financial Relationships |
| David Allison, PhD, FTOS | <p>Consultant relationship with Alkermes Inc. (Pharmaceuticals); Kaleido Biosciences (Pharmaceuticals); and Novo Nordisk (Pharmaceuticals)</p> <p>Researcher relationship with Researcher relationship with Eli Lilly and Company (Pharmaceuticals); Soleno Therapeutics (Pharmaceuticals); WW (Weight Management/Medical Food); American Egg Board (Non-medical Food); Haas Avocado Board (Non-medical Food); Mars Inc. (Non-medical Food); Alliance for Potato Research and Education (Non-medical Food); and National Cattlemen's Beef Association (Non-medical Food)</p> <p>Stock options relationship with Big Sky Health (Medical Device)</p> <p>Advisor relationship with Novo Nordisk (Pharmaceuticals) and Big Sky Health (Medical Device)</p> |
| Kelly Allison, PhD | No Relevant Financial Relationships |
| Saleh Alqahtani, MD | No Relevant Financial Relationships |
| Mark Andermann, PhD | No Relevant Financial Relationships |
| John Apolzan, PhD, FTOS | Researcher relationship with WW (Weight Management/Medical Food) and Mizkan Holdings Co., Ltd.(Non-medical Food) |
| Yeka Aponte, PhD | No Relevant Financial Relationships |
| Bradley Appelhans, PhD | No Relevant Financial Relationships |
| Jamy Ard, MD | <p>Advisor relationship with Level2 (Weight Management).</p> <p>Consultant relationship with Calibrate (Weight Management); Eli Lilly (Pharmaceuticals); Regeneron (Medical Device); Novo Nordisk (Pharmaceuticals); and Brightseed (Biomedical).</p> <p>Researcher relationship with Boehringer Ingelheim (Pharmaceuticals); Epitomee, Inc.(Medical Device); UnitedHealth Group (Biomedical); KVKTech (Pharmaceuticals); WW (Weight Management/Medical Food); and Nestle Healthcare Nutrition (Medical Food).</p> |
| Kirsten Arm, MPH, RDN | No Relevant Financial Relationships |
| Sarah Armstrong, MD | No Relevant Financial Relationships |
| Beyza Aydin, MD | No Relevant Financial Relationships |
| Victoria Bae-Jump, PhD, MD | Researcher relationship with Merck (Pharmaceutical/Biomedical); Chimerix (Pharmaceutical/Biomedical) and Genentech (Pharmaceuticals); Independent Contractor relationship with Sphaera (Pharmaceuticals) and Cardero (Pharmaceuticals); Consultant relationship with Eisai (Pharmaceuticals) |

| Name of Presenter | Relevant Financial Relationships |
|--|--|
| Simar Bajaj | No Relevant Financial Relationships |
| Geoff Ball, PhD, RD, FTOS | Advisor relationship with Novo Nordisk Canada (Pharmaceuticals) |
| Sarah Barlow, MD, MPH | No Relevant Financial Relationships |
| Simon Barquera, MD, MS, PhD, FTOS | No Relevant Financial Relationships |
| Louise Baur | Speaker and Advisor relationships with Novo Nordisk (Pharmaceuticals) |
| Jennifer Bea, PhD | Researcher relationship with Disarm Therapeutics (Pharmaceuticals) |
| Tiffani Bell Washington, MD, MPH, FAPA, DABOM, DABLM | No Relevant Financial Relationships |
| Jerica Berge, PhD, MPH, LMFT | No Relevant Financial Relationships |
| Hans-Rudolf Berthoud, PhD | Consultant relationship with Novo Nordisk (Pharmaceuticals) |
| Dan Bessesen, MD, FTOS | Speaker relationship with Novo Nordisk (Pharmaceuticals); Consultant relationship with Lilly (Pharmaceuticals) |
| J. Nicholas Betley, PhD | No Relevant Financial Relationships |
| Diego Bohorquez, PhD | No Relevant Financial Relationships |
| Sarah Borengasser, PhD | No Relevant Financial Relationships |
| Tito Borner, PhD | No Relevant Financial Relationships |
| Molly Bray, PhD | No Relevant Financial Relationships |
| Kristal Brown, PhD, MSPH | No Relevant Financial Relationships |
| Barto Burguera, MD, PhD | Researcher relationship with Novo Nordisk (Pharmaceuticals) |
| Ryan Burns, BAppSc, MChD, MPH | Publicly-traded Stock relationship with Eli Lilly (Pharmaceuticals) |
| Cailin Caspi, ScD | No Relevant Financial Relationships |
| Omni Cassidy, PhD | No Relevant Financial Relationships |
| Patrick Catalano, MD | No Relevant Financial Relationships |
| Delwyn Catley, PhD | No Relevant Financial Relationships |
| John Cawley, PhD | Consultant relationship with Novo Nordisk (Pharmaceuticals) |
| Jean-Philippe Chaput, PhD | No Relevant Financial Relationships |
| Liuyi Chen | No Relevant Financial Relationships |
| Julie Christianson, PhD | Researcher relationship with Biogen (Pharmaceuticals) |
| Lizeth Cifuentes, MD | No Relevant Financial Relationships |
| Jaime Coffino, PhD, MPH | No Relevant Financial Relationships |
| Anita Courcoulas, MD, MPH, FACS | No Relevant Financial Relationships |
| Seth Creasy, PhD | No Relevant Financial Relationships |
| Melanie Cree-Green | Consultant relationship with Pollie (Medical Device) |
| Noe Crespo, PhD | No Relevant Financial Relationships |

| Name of Presenter | Relevant Financial Relationships |
|--|---|
| Hassan Dashti, PhD, RD | No Relevant Financial Relationships |
| Ashlesha Datar, PhD | No Relevant Financial Relationships |
| Jaimie Davis, RD, PHD | No Relevant Financial Relationships |
| Bart de Jonghe, PhD | Researcher relationship with Eli Lilly (Pharmaceuticals) |
| Nikhil Dhurandhar, MS, LCEH, PhD, FTOS | Researcher relationship with The Beef Checkoff (Non-medical Food); Insparin (Pharmaceuticals); Novo Nordisk (Pharmaceuticals); and American Egg Board (Non-medical Food) Advisor relationship with Medifast (Weight Management/Medical Food) |
| Adeline Divoux, PhD | No Relevant Financial Relationships |
| Emily Duffy, MPH | No Relevant Financial Relationships |
| Wesley Dutton, MD | No Relevant Financial Relationships |
| Leonard Egede, MD, MS | No Relevant Financial Relationships |
| Dawn Eichen, PhD | No Relevant Financial Relationships |
| Ihuoma Eneli, MD, MS | Researcher relationship with Rhythm Pharmaceuticals (Pharmaceuticals) |
| Melissa Erickson, PhD | No Relevant Financial Relationships |
| Mary Evans, PhD | No Relevant Financial Relationships |
| Ismaa Sadaf Farooqi, MBChB (Hons), PhD, FRCP, FMedSci, DSc | Consultant relationship with Rhythm Pharmaceuticals (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals). Speaker relationship with Eli Lilly (Pharmaceuticals). |
| Cristina Fernandez, MD | No Relevant Financial Relationships |
| Lauren Fiechtner, MD, MPH | No Relevant Financial Relationships |
| Alison Field, ScD, FTOS | No Relevant Financial Relationships |
| David Fields, PhD | No Relevant Financial Relationships |
| Stephanie Fitzpatrick, PhD | Employee relationship with WW International Inc. (Weight Management/Medical Food) Note: This financial conflict is not relevant because the content of session is not related to the business lines or products of her employer. |
| Kathryne Foos | No Relevant Financial Relationships |
| Evan Forman, PhD | Advisor relationship with Nutrisystem (Weight Management/Medical Food) |
| Vida Forouhar, BSc | No Relevant Financial Relationships |
| Samantha Fortin, PhD | No Relevant Financial Relationships |
| Carolynn Francavilla Brown, MD, D-ABOM, FOMA | Independent Contractor relationship with Optavia (Medical Food) Publicly-traded Stock relationship with Eli Lilly (Pharmaceuticals) |
| Jennifer Franceschelli Hosterman, DO, FAAP | No Relevant Financial Relationships |
| Kelsey Gabel, PhD, RD | No Relevant Financial Relationships |

| Name of Presenter | Relevant Financial Relationships |
|----------------------------------|---|
| Christopher Gardner, PhD | Initial report: No Relevant Financial Relationships Note: During his presentation, Dr. Gardner verbally added a Consultant relationship with Zoe (Diagnostic Laboratory) |
| Ariana Garza, MPH | No Relevant Financial Relationships |
| Laura Gibson, PhD | No Relevant Financial Relationships |
| Erin Giles, PhD | No Relevant Financial Relationships |
| Alyson Goodman, MD, MPH | No Relevant Financial Relationships |
| Bret Goodpaster, PhD | No Relevant Financial Relationships |
| Johanne Gormsen, MD | No Relevant Financial Relationships |
| Marcio Griebeler, MD | Contracted Research relationship with Novo Nordisk (Pharmaceuticals) |
| Karen Grothe, PhD | No Relevant Financial Relationships |
| Anna Grummon, PhD, MSPH | No Relevant Financial Relationships |
| Matthew Haemer, MD, MPH | No Relevant Financial Relationships |
| Erin Hager, PhD | No Relevant Financial Relationships |
| Sarah Hampl, MD | No Relevant Financial Relationships |
| Joan Han, MD | Researcher relationship with Rhythm Pharmaceuticals (Pharmaceuticals) |
| Kristal Hartman | Patient Steering Committee relationship with Pfizer (Pharmaceuticals) |
| Anna Hayes, PhD | No Relevant Financial Relationships |
| Bill Heerman, MD MPH | No Relevant Financial Relationships |
| Sharon Herring, MD, MPH | No Relevant Financial Relationships |
| Emily Hill, PhD, RDN | No Relevant Financial Relationships |
| Jennie Hill, PhD | No Relevant Financial Relationships |
| Joseph Hill, MD, PhD | No Relevant Financial Relationships |
| Emily Hohman, PhD | No Relevant Financial Relationships |
| Jonathan Hommel, PhD | No Relevant Financial Relationships |
| Denise Houston, PhD, RD | No Relevant Financial Relationships |
| Carrie Howell, PhD | No Relevant Financial Relationships |
| Sophia Hua, PhD, MPH | No Relevant Financial Relationships |
| Autumn Hullings, MPH | No Relevant Financial Relationships |
| Roberta Ienca, MD | No Relevant Financial Relationships |
| Angela Incollingo Rodriguez, PhD | No Relevant Financial Relationships |
| Chandra Jackson, PhD, MS | No Relevant Financial Relationships |
| Bhav Jain | No Relevant Financial Relationships |
| Danielle Jake-Schoffman, PhD | No Relevant Financial Relationships |

| Name of Presenter | Relevant Financial Relationships |
|--------------------------------|---|
| John Jakicic, PhD, FTOS, FACSM | Advisor relationship with Wondr Health Inc. (Weight Management); and WW International Inc. (Weight Management/Medical Food); Researcher relationship with Epitee Medical Inc. (Pharmaceuticals); Consultant relationship with Educational Initiatives Inc. (Weight Management) |
| Ania Jastreboff, MD, PhD | <p>Advisor relationship with Novo Nordisk (Pharmaceuticals); Eli Lilly (Pharmaceuticals); Boehringer Ingelheim (Pharmaceuticals); Pfizer (Pharmaceuticals); Rhythm Pharmaceuticals (Pharmaceuticals); WW (Weight Management/Medical Food); Intellihealth (Weight Management Telehealth-TOS conflict).</p> <p>Consultant relationship with Scholar Rock (Pharmaceuticals).</p> <p>Researcher relationship with Novo Nordisk (Pharmaceuticals).</p> <p>Stock Options relationship with IntelliHealth (Weight Management Telehealth-TOS conflict).</p> |
| Matthew Jeans, MS, MM | No Relevant Financial Relationships |
| Hiba Jebeile, PhD APD | No Relevant Financial Relationships |
| Elissa Jelalian, PhD | Corporate Advisory Board relationship with WW (Weight Management/Medical Food) |
| Veronica Johnson, MD, FAAP | Advisor relationship with Novo Nordisk (Pharmaceuticals) |
| Bradley Johnston, PhD | No Relevant Financial Relationships |
| Scott Kahan, MD, MPH, FTOS | <p>Advisor relationship with Lilly (Pharmaceuticals); Currax (Pharmaceuticals); and Gelesis (Medical Device).</p> <p>Consultant relationship with Vivus (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals).</p> |
| Kathryn Kaiser, PhD | No Relevant Financial Relationships |
| Lee Kaplan, MD, PhD, FTOS | <p>Consultant relationship with Altimmune, Amgen, Boehringer Ingelheim, Gilead Sciences, Lilly, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals, Xeno Biosciences (All Pharmaceuticals).</p> <p>Consultant relationship with Johnson & Johnson, Gelesis, GI Windows, GI Dynamics (all Medical Device).</p> <p>Consultant relationship with Intellihealth and Optum (Both Weight Management).</p> |
| Erica Kenney, ScD, MPH | No Relevant Financial Relationships |
| Wendy King, PhD | No Relevant Financial Relationships |
| Eliza Kinsey, PhD, MPH | No Relevant Financial Relationships |

| Name of Presenter | Relevant Financial Relationships |
|------------------------------|--|
| Samuel Klein, MD | <p>Scientific Advisory Board relationship with Merck (Pharmaceuticals) and Altimmune (Pharmaceuticals).</p> <p>Consultant relationship with Lilly (Pharmaceuticals); Alnyln (Pharmaceuticals); and B2M (Medical Device).</p> |
| Christopher Kline, PhD | No Relevant Financial Relationships |
| Kai Ling Kong, PhD | No Relevant Financial Relationships |
| Theodore Kyle, RPh, MBA | <p>Advisor relationship with Gelesis (Pharmaceuticals) and Nutri System (Weight Management/Medical Food).</p> <p>Speaker relationship with Johnson & Johnson (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals).</p> |
| Matthew Landry, PhD, RDN | No Relevant Financial Relationships |
| Helena Laroche, MD | Publicly-traded Stock relationship with Walgreens (Pharmaceuticals) and Viatrix (Pharmaceuticals) |
| Maren Laughlin, PhD | No Relevant Financial Relationships |
| Carl Lavie, MD | Speaker relationship with PAI Health (Medical Device) |
| Elizabeth Lawson, MD, MMSc | <p>Stock Options relationship with Oxytocin Therapeutics Inc. (Pharmaceuticals);</p> <p>Advisor relationship with Oxytocin Therapeutics Inc. (Pharmaceuticals);</p> <p>Researcher relationship with Tonix Pharmaceuticals (Pharmaceuticals)</p> |
| Kristina Lewis, MD, MPH, SM | No Relevant Financial Relationships |
| Li Li | No Relevant Financial Relationships |
| Marissa Lightbourne, MD, MPH | No Relevant Financial Relationships |
| Shuhao Lin | No Relevant Financial Relationships |
| Karen Lindsay, PhD, RDN | No Relevant Financial Relationships |
| Sheridan Littleton, BS | No Relevant Financial Relationships |
| Holly Lofton, MD, DABOM | <p>Advisor relationship with Novo Nordisk (Pharmaceuticals) and Currax Inc (Pharmaceuticals).</p> <p>Speaker relationship with Novo Nordisk (Pharmaceuticals).</p> <p>Researcher relationship with Novo Nordisk (Pharmaceuticals) and Eli Lilly (Pharmaceuticals).</p> |
| John Long | No Relevant Financial Relationships |
| Mette Ludwig, PhD | No Relevant Financial Relationships |
| Andrew Lutkewitte, PhD | No Relevant Financial Relationships |

| Name of Presenter | Relevant Financial Relationships |
|---|--|
| Virgine Mansuy-Aubert, PhD | No Relevant Financial Relationships |
| Patricia Markby | No Relevant Financial Relationships |
| Stephanie Mayne, PhD, MHS | No Relevant Financial Relationships |
| Kelsey McAlister | No Relevant Financial Relationships |
| Jeremy McConnell, MD, FOMA | Speaker relationship with Novo Nordisk (Pharmaceuticals) |
| Lacey McCormack, PhD, MPH, RD | No Relevant Financial Relationships |
| Ying Meng, PhD, RN | No Relevant Financial Relationships |
| Jacob Mey, PhD, RD | No Relevant Financial Relationships |
| Elizabeth Mietlicki-Baase, PhD | No Relevant Financial Relationships |
| Iva Miljkovic, MD, PhD, FAHA | No Relevant Financial Relationships |
| Nia Mitchell, MD, MPH | No Relevant Financial Relationships |
| Violeta Moize Arcone, RD, PhD | No Relevant Financial Relationships |
| Kerrie Moreau, PhD | No Relevant Financial Relationships |
| Julia Mueller, PhD | No Relevant Financial Relationships |
| Aviva Musicus, ScD | No Relevant Financial Relationships |
| Spencer Nadolsky, DO, Dipl. ABOM and ABCL | No Financial Relationships Relevant per ACCME standards. Ownership of GetLeanRx Consulting LLC (Weight Management-TOS conflict) |
| Patty Nece, JD | Consultant relationship with Novo Nordisk (Pharmaceuticals) |
| Angela Odoms-Young, PhD | No Relevant Financial Relationships |
| Ashleigh Oliveira | No Relevant Financial Relationships |
| Madeleine Oudin, PhD | No Relevant Financial Relationships |
| Jaume Padilla, PhD | No Relevant Financial Relationships |
| Tusharkumar Patel, PhD | No Relevant Financial Relationships |
| Elizabeth Paul | No Relevant Financial Relationships |
| M. Yanina Pepino, PhD | No Relevant Financial Relationships |
| Michael Perri, PhD | No Relevant Financial Relationships |
| Courtney Peterson, PhD | No Relevant Financial Relationships |
| Joshua Petimar, ScD | No Relevant Financial Relationships |
| Sean Phelan, PhD, MPH | No Relevant Financial Relationships |
| Chantal Pileggi, PhD | No Relevant Financial Relationships |
| Monique Potvin Kent, PhD | No Relevant Financial Relationships |
| Lisa Powell, PhD | No Relevant Financial Relationships |
| Richard Pratley, MD | Researcher relationship with Hanmi Pharmaceutical Co. (Pharmaceuticals); Novo Nordisk (Pharmaceuticals); Metaventon (Pharmaceuticals); and Poxel (Pharmaceuticals) |

| Name of Presenter | Relevant Financial Relationships |
|--------------------------------|--|
| John Prom, BS | No Relevant Financial Relationships |
| Lauren Ptomey, PhD | No Relevant Financial Relationships |
| Jonathan Purnell, MD, FTOS | Consultant relationship with Novo Nordisk (Pharmaceuticals); Boehringer Ingelheim (Pharmaceuticals); and Luciole (Pharmaceuticals) |
| David Raubenheimer, PhD | No Relevant Financial Relationships |
| Eric Ravussin, PhD | <p>Researcher relationship with Eli Lilly (Pharmaceuticals); Novartis (Pharmaceuticals); and Sanofi-Avantis (Pharmaceuticals).</p> <p>Consultant relationship with Eli Lilly (Pharmaceuticals); Merck (Pharmaceuticals); Amway (Supplement); Kintai Therapeutics (Biomedical); YSOPIA (Biomedical).</p> |
| Hollie Raynor, PhD | No Relevant Financial Relationships |
| Hollie Raynor, PhD | No Relevant Financial Relationships |
| Leanne Redman, PhD, FTOS | No Relevant Financial Relationships |
| Andrea Richardson, PhD, MPH | No Relevant Financial Relationships |
| Thomas Robinson, MD, MPH, FTOS | Advisor relationship with WW International Inc. (Weight Management/Medical Food) |
| Griffin Rodgers, MD, MACP | No Relevant Financial Relationships |
| Renee Rogers, PhD | Consultant relationship with Wondr Health (Weight Management) |
| Maria Romanova, MD | No Relevant Financial Relationships |
| Cara Ruggiero, PhD, RD | No Relevant Financial Relationships |
| Donna Ryan, MD, FTOS, MABOM | <p>Advisor relationship with Altimmune (Pharmaceuticals); Alyvent (Weight Management); Amgen (Pharmaceuticals); Boehringer Ingelheim (Pharmaceuticals); Calibrate (Weight Management); Epitomee (Medical Device); Gila Therapeutics (Pharmaceuticals); Lilly (Pharmaceuticals); Novo Nordisk (Pharmaceuticals); Phenomix (Biomedical); Real Appeal (Weight Management); Sanofi (Pharmaceuticals); Wondr Health (Weight Management); YSOPIA (Pharmaceuticals); and Zealand (Pharmaceuticals).</p> <p>Consulting Fee relationship with Scientific Intake (Medical Device) and Xeno Bioscience (Pharmaceuticals).</p> <p>Data Safety Monitoring Board for Rhythm (setmelanotide) relationship with IQVIA (Biomedical).</p> <p>Steering Committee relationship with Novo Nordisk (Pharmaceuticals).</p> <p>Speaker relationship with IFA Celtic (Pharmaceuticals) and Novo Nordisk (Pharmaceuticals).</p> <p>Stock options relationship with Calibrate (Weight Management); Scientific Intake (Medical Device); Xeno Bioscience (Pharmaceuticals); Roman (Weight Management); and Epitomee (Medical Device).</p> |

| Name of Presenter | Relevant Financial Relationships |
|--------------------------------------|--|
| Amadeo Salvador, PhD | No Relevant Financial Relationships |
| Sarah Salvy, PhD | No Relevant Financial Relationships |
| Lee Sanders, MD, MPH | No Relevant Financial Relationships |
| Shohinee Sarma, MD MPH FRCPC | No Relevant Financial Relationships |
| David Sarwer, PhD | Consultant relationship with NovoNordisk (Pharmaceuticals) and Ethicon (Medical Device) |
| Katherine Saunders, MD | No Financial Relationships Relevant per ACCME standards. Ownership/management interest relationship with Intellihealth (Weight Management Telehealth-TOS conflict) |
| Leah Schumacher, PhD | No Relevant Financial Relationships |
| Randy Seeley, PhD | <p>Advisor relationship with ShouTi Pharma (Pharmaceuticals); Scohia (Pharmaceuticals); and Fractyl (Medical Device).</p> <p>Consultant relationship with Novo Nordisk (Pharmaceuticals).</p> <p>Researcher relationship with Novo Nordisk (Pharmaceuticals); Astra Zeneca (Pharmaceuticals); and Fractyl (Medical Device).</p> <p>Stock Options relationship with Calibrate (Weight Management) and Rewind (Weight Management).</p> |
| Vasavi Shabrish, PhD | No Relevant Financial Relationships |
| Alpana Shukla, MD, FTOS | Researcher relationship with Novo Nordisk (Pharmaceuticals) |
| Roberto Simons-Linares, MD | No Relevant Financial Relationships |
| Kanakadurga Singer, MD | No Relevant Financial Relationships |
| Caitlin Smith, PhD | No Relevant Financial Relationships |
| Diana Soria, MSc, PhD | No Relevant Financial Relationships |
| Mai Spaulding | No Relevant Financial Relationships |
| Ruth St Fleur, PhD | No Relevant Financial Relationships |
| Sarah Stern, PhD | No Relevant Financial Relationships |
| Marie-Pierre St-Onge, PhD, CSH, FAHA | Speaker relationship with PharmaVite (Supplement); Consultant relationship with Nestle (Medical Food) and PepsiCo (Non-Medical Food) |
| Baiyang Sun, MPH | No Relevant Financial Relationships |
| Marius Svanevik, MD, PhD | No Relevant Financial Relationships |
| Lindsey Taillie, PhD, MPH | No Relevant Financial Relationships |
| Alexander Tam, BA | No Relevant Financial Relationships |
| Deborah Tate, PhD | <p>Advisor relationship with WW (Weight Management/Medical Food) and Wondr Health (Weight Management).</p> <p>Researcher relationship with WW (Weight Management/Medical Food).</p> |

| Name of Presenter | Relevant Financial Relationships |
|---|--|
| Simeon Taylor, MD, PhD | Consultant relationship with Ionis Pharmaceuticals (Pharmaceuticals) |
| June Tester, MD, MPH | No Relevant Financial Relationships |
| Christoph Thaiss, PhD | No Relevant Financial Relationships |
| Gita Thapaliya, PhD | No Relevant Financial Relationships |
| Diana Thomas, PhD, FTOS | No Relevant Financial Relationships |
| Karen Tinlin | No Relevant Financial Relationships |
| Kristy Townsend, PhD | No Relevant Financial Relationships |
| Gina Tripicchio, PhD, MSEd | No Relevant Financial Relationships |
| Louise Tully, RNutr, PhD | No Relevant Financial Relationships |
| Brie Turner-McGrievy, PhD, MS, RD, FTOS | No Relevant Financial Relationships |
| Yigit Unlu, MD | No Relevant Financial Relationships |
| Sarvenaz Vandyousefi, PhD, MS, RD | No Relevant Financial Relationships |
| Aditi Vasan, MD, MSHP | No Relevant Financial Relationships |
| Alaina Vidmar, MD | No Relevant Financial Relationships |
| Thomas Wadden, PhD | Advisor relationship with WW (Weight Management/Medical Food) and Novo Nordisk (Pharmaceuticals). |
| Monica Wang, ScD | No Relevant Financial Relationships |
| Leah Whigham, PhD, FTOS | No Relevant Financial Relationships |
| Gretchen White, PhD | No Relevant Financial Relationships |
| Elizabeth Widen, PhD, RD | Researcher relationship with Egg Nutrition Center (Non-medical Food) and National Cattlemen's Beef Association (Non-medical Food) |
| Denise Wilfley, PhD | No Relevant Financial Relationships |
| Nathan Winn, PhD | No Relevant Financial Relationships |
| David Wright, PhD | No Relevant Financial Relationships |
| Marc Wuerdeman, MD | No Relevant Financial Relationships |
| Holly Wyatt, MD | <p>Ownership of Shakabuku LLC (Weight Management-TOS conflict/not relevant by ACCME standards).</p> <p>Researcher relationship with Gelesis (Medical Device); Epitomee Medical Ltd (Medical Device); Novo Nordisk (Pharmaceuticals); General Mills (Non-medical Food) and National Cattleman's Beef Association (Non-medical Food).</p> <p>Royalties relationship with State of Slim book (Weight Management).</p> <p>Advisor relationship with Gelesis (Medical Device).</p> <p>Stock Options relationship with Ro (Weight Management).</p> |
| Chittaranjan Yajnik, MD, FRCP | No Relevant Financial Relationships |

| Name of Presenter | Relevant Financial Relationships |
|-------------------------------|---|
| Jeffrey Zigman, MD, PhD, FTOS | Publicly-traded Stock relationship with Medtronic (Medical Device); Researcher relationship with Novo Nordisk (Pharmaceuticals); Consultant relationship with Dexcel Pharma (Pharmaceuticals) |

Planner Disclosures: TOS Annual Meeting Program Committee disclosures:

| Name | Planning Committee Role | Relevant Financial Relationships |
|--------------------------------|--|---|
| Allison, Kelly (PhD) | Chair | No Relevant Financial Relationships |
| White, Ursula (PhD) | Co-Chair | No Relevant Financial Relationships |
| Brown, Rebecca (MD) | T1: Metabolism/Integrative Physiology Chair | Contracted Research relationship with Regeneron Pharmaceuticals (Pharmaceuticals). In kind research support relationship with Akcea Therapeutics (Pharmaceuticals) and Amryt Pharma (Pharmaceuticals). |
| Sparks, Lauren (PhD) | T1: Metabolism/Integrative Physiology Co-Chair | No Relevant Financial Relationships |
| Allerton, Timothy (PhD, RCEP) | T1: Metabolism/Integrative Physiology | No Relevant Financial Relationships |
| Rojas-Rodriguez, Raziell (PhD) | T1: Metabolism/Integrative Physiology | No Relevant Financial Relationships |
| Stewart, Delisha (PhD) | T1: Metabolism/Integrative Physiology | No Relevant Financial Relationships |
| Wingo, Brooks (PhD) | T1: Metabolism/Integrative Physiology | No Relevant Financial Relationships |
| Leininger, Gina (PhD) | T2: Neuroscience Chair | No Relevant Financial Relationships |
| Noble, Emily (PhD) | T2: Neuroscience Co-Chair | No Relevant Financial Relationships |
| Alhadeff, Amber (PhD) | T2: Neuroscience | No Relevant Financial Relationships |
| Sandoval, Darleen (PhD) | T2: Neuroscience | No Relevant Financial Relationships |
| Thaler, Josh (MD, PhD) | T2: Neuroscience | Publicly-traded stock relationship with Pfizer (Pharmaceuticals) |
| Lowe, Michael (PhD) | T3: Intervention/Clinical Studies Chair | No Relevant Financial Relationships |
| Raynor, Hollie (PhD) | T3: Intervention/Clinical Studies Co-Chair | No Relevant Financial Relationships |
| Catenacci, Victoria (MD) | T3: Intervention/Clinical Studies | No Relevant Financial Relationships |
| Igel, Leon (MD, FACP, FTOS) | T3: Intervention/Clinical Studies | Salary relationship with Intellihealth (Weight Management Telehealth-TOS conflict, Not an ACCME Conflict) |

| | | |
|--|---|--|
| Jelalian, Elissa (PhD) | T3: Intervention/Clinical Studies | Corporate Advisory Board relationship with WW (Weight Management/Medical Food) |
| Messiah, Sarah (PhD, MPH, FTOS) | T4: Population Health Chair | No Relevant Financial Relationships |
| Myers, Candice (PhD) | T4: Population Health Co-Chair | No Relevant Financial Relationships |
| Arlinghaus, Katherine (PhD, RD) | T4: Population Health | No Relevant Financial Relationships |
| Saslowky, David (PhD) | T4: Population Health | No Relevant Financial Relationships |
| Shams-White, Marissa (PhD, MSTOM, MS, MPH) | T4: Population Health | No Relevant Financial Relationships |
| Tchang, Beverly (MD) | T5: Clinical/Professional Practice Chair | Consulting Fee relationship with Novo Nordisk (Pharmaceuticals) |
| Shah, Meera (MD) | T5: Clinical/Professional Practice Co-Chair | No Relevant Financial Relationships |
| Fitch, Angela (MD) | T5: Clinical/Professional Practice | Corporate Advisory Board relationship with Gelesis (Medical Device); Jenny Craig (Weight Management); and Novo Nordisk (Pharmaceuticals). Consulting Fee relationship with Ms Medicine (Weight Management). Stock Options relationship with Found Health (Weight Management) and Suvie (Food). |
| Goss, Amy (PhD, RDN) | T5: Clinical/Professional Practice | No Relevant Financial Relationships |
| Griebeler, Marcio (MD) | T5: Clinical/Professional Practice | Contracted Research relationship with Novo Nordisk (Pharmaceuticals) |
| Pearl, Rebecca (PhD) | T6: Policy/Public Health Chair | No Relevant Financial Relationships |
| Luke, Amy (PhD) | T6: Policy/Public Health Co-Chair | No Relevant Financial Relationships |
| Bragg, Marie (PhD) | T6: Policy/Public Health | No Relevant Financial Relationships |
| Elbel, Brian (PhD, MPH) | T6: Policy/Public Health | No Relevant Financial Relationships |
| Musicus, Aviva (ScD) | T6: Policy/Public Health | No Relevant Financial Relationships |
| Comuzzie, Anthony (PhD, FTOS) | TOS CEO | No Relevant Financial Relationships |
| Bessesen, Dan (MD, FTOS) | TOS President (Governance Liaison) | Speaker relationship with Novo Nordisk (Pharmaceuticals). Consultant relationship with Lilly (Pharmaceuticals). |

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee. Two members of the committee, Alpana Shukla and Meera Shaw, stepped down from the committee when they developed a conflict *after* planning was complete.

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated November 4, 2022 v2.